Suhagra 100

Product Information: Suhagra 100 (Sildenafil Citrate 100mg)

This refined product information provides a concise yet comprehensive overview of Suhagra 100. Always consult a healthcare professional for personalized advice and before starting or changing any treatment.

1. Product Identification:

• Product Name: Suhagra 100
• Active Ingredient: Sildenafil Citrate
• Strength: 100 mg per tablet
• Pharmaceutical Form: Tablet
• Manufacturer: Cipla Ltd., India

2. Therapeutic Uses:

• Erectile Dysfunction (ED): Primarily indicated for the treatment of erectile dysfunction in adult males, enabling the achievement and maintenance of an erection sufficient for satisfactory sexual intercourse. Its action is contingent upon sexual stimulation.
• Pulmonary Arterial Hypertension (PAH): Sildenafil, the active component, is also used to treat pulmonary arterial hypertension in adults, improving exercise capacity and potentially slowing disease progression by relaxing pulmonary blood vessels. (Note: Dosage and formulation for PAH may differ from Suhagra 100).

3. Pharmacological Action:

Sildenafil Citrate is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type¹ 5 (PDE5).

• In Erectile Dysfunction: During sexual stimulation, nitric oxide (NO) is released in the penis, activating guanylate cyclase, leading to increased levels of cGMP. cGMP causes relaxation of smooth muscles in the corpus cavernosum, allowing increased blood inflow and subsequent erection. Sildenafil inhibits PDE5, preventing the breakdown of cGMP, thereby enhancing and prolonging the erectile response to sexual stimulation.
• In Pulmonary Arterial Hypertension: Sildenafil inhibits PDE5 in the pulmonary vasculature, leading to vasodilation and a reduction in pulmonary vascular resistance and pressure.

4. Dosage and Administration (for Erectile Dysfunction):

• Administer orally with water, with or without food. Absorption may be delayed if taken with a high-fat meal.
• The typical recommended starting dose is 50 mg, taken as needed approximately 30 minutes to 1 hour before sexual activity.
• Based on efficacy and tolerability, the dose may be increased to a maximum of 100 mg or decreased to 25 mg.
• The maximum recommended frequency of dosing is once per day.
• Adhere strictly to the physician’s prescribed dosage and timing.

5. Contraindications (Do Not Use If You Have):

• Known hypersensitivity to sildenafil or any excipients in the formulation.
• Concurrent use of any form of organic nitrates (e.g., nitroglycerin, isosorbide mononitrate or dinitrate) due to the risk of severe hypotension.
• Co-administration with riociguat, a guanylate cyclase stimulator.
• Severe cardiovascular disorders (e.g., unstable angina, severe heart failure, recent myocardial infarction or stroke within the last 3-6 months).
• Severe hepatic impairment.
• Hypotension (blood pressure < 90/50 mmHg).
• Certain hereditary degenerative retinal disorders, such as retinitis pigmentosa (in some patients).
• A history of non-arteritic anterior ischemic optic neuropathy (NAION) related to previous PDE5 inhibitor use.

6. Warnings and Precautions (Consult Your Doctor Before Use If You Have):

• Cardiovascular risk factors or pre-existing cardiovascular disease. Sexual activity carries a potential cardiac risk in individuals with pre-existing heart conditions.
• Conditions that may predispose to priapism (prolonged erection > 4 hours), such as sickle cell anemia, multiple myeloma, or leukemia. Seek immediate medical attention if priapism occurs.
• Anatomical deformation of the penis (e.g., Peyronie’s disease).
• Bleeding disorders or active peptic ulcer disease.
• Renal impairment (dosage adjustment may be necessary).
• Hepatic impairment (lower starting dose may be considered).
• Sudden decrease or loss of vision or hearing, which may be a rare side effect associated with PDE5 inhibitors. Discontinue use and seek immediate medical attention if this occurs.
• Concomitant use of alpha-blockers (may lead to symptomatic hypotension; initiate sildenafil at a lower dose).
• Concomitant use of potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) may increase sildenafil exposure (lower starting dose recommended).

7. Potential Side Effects:

• Common: Headache, flushing, dyspepsia (indigestion), nasal congestion, dizziness, visual disturbances (e.g., blurred vision, changes in color vision). These are usually mild and transient.
• Uncommon: Palpitations, tachycardia, hypotension, hypertension, vomiting, nausea, dry mouth, rash, eye pain, tinnitus.
• Rare: Myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, seizures, anxiety, syncope, epistaxis, priapism, sudden decrease or loss of vision or hearing.

Report any persistent or troublesome side effects to your doctor immediately.

8. Drug Interactions (Inform Your Doctor About All Medications You Are Taking):

• Nitrates: Absolutely contraindicated (see Contraindications).
• Riociguat: Absolutely contraindicated (see Contraindications).
• Alpha-blockers: May lead to additive blood pressure lowering effects. Initiate sildenafil at a lower dose.
• Antihypertensives: May have additive blood pressure lowering effects.
• CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, erythromycin, cimetidine, ritonavir): May increase sildenafil plasma concentrations, potentially increasing the risk of side effects. Dosage adjustment of sildenafil may be necessary.
• CYP3A4 Inducers (e.g., rifampin, phenytoin, carbamazepine): May decrease sildenafil plasma concentrations, potentially reducing its efficacy.
• Other PDE5 Inhibitors: Concurrent use is not recommended due to the potential for increased side effects.

9. Use in Specific Populations:

• Men: Indicated for adult males only.
• Women: Not indicated for use in women.
• Pediatric Population: Not indicated for use in individuals under 18 years of age.
• Elderly: May be more susceptible to side effects. A lower starting dose may be considered.
• Renal and Hepatic Impairment: Dosage adjustments may be necessary. Consult your physician.

10. Overdosage:

In cases of overdose, standard supportive measures should be adopted as needed. Dialysis is not expected to accelerate sildenafil clearance due to its high protein binding and large volume of distribution. Seek immediate medical attention if an overdose is suspected.

11. Storage:

Store at room temperature (15-30°C or 59-86°F), away from moisture, heat, and direct light. Keep out of reach of children and pets.

12. Availability:

Suhagra 100 is a prescription-only medicine and must be obtained with a valid prescription from a registered medical practitioner.

Disclaimer: This refined product information is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any² medical condition. Self-treatment can be harmful.